October 02, 2025 a 08:39 am
REGN: Analysts Ratings - Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. operates in a dynamic field of biopharmaceuticals, focusing on the discovery and commercialization of innovative treatments. Analyst ratings indicate a generally positive outlook, with a significant number maintaining 'Buy' or 'Strong Buy' recommendations. The company's robust portfolio and strategic collaborations support this sentiment despite occasional market volatility.
Historical Stock Grades
Analysis of the latest analyst ratings for Regeneron Pharmaceuticals up to October 2025 shows a generally steady position with favorable sentiment. The data reflects a predominant 'Buy' and 'Strong Buy' consensus, suggesting ongoing confidence in the company's long-term potential.
| Recommendation | Count | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 15 | |
| Hold | 6 | |
| Sell | 0 | |
| Strong Sell | 1 |
Sentiment Development
Over the past year, the sentiment towards Regeneron Pharmaceuticals has shifted, with a noticeable decrease in 'Strong Buy' ratings, counterbalanced by stable 'Buy' recommendations. The total number of ratings has seen minor fluctuations, but the consensus has largely favored holding or buying the stock.
- An overall decline in 'Strong Buy' sentiments since early 2025.
- 'Hold' recommendations saw a slight increase in mid-2025, potentially reflecting cautious optimism.
- Stable 'Buy' recommendations suggest continued market confidence.
Percentage Trends
The percentage distribution of analyst recommendations for Regeneron over the past year highlights a shift towards more conservative stances. The decrease in 'Strong Buy' is offset by consistent 'Buy' recommendations, indicating potential risk aversion in the market.
- 'Strong Buy' ratings decreased from 25% to approximately 15% in the last six months.
- 'Buy' recommendations maintained around 50-60% consistency.
- 'Hold' ratings increased, indicating a trend towards stability and caution.
- Minimal representation of 'Sell' and 'Strong Sell', underscoring ongoing favorable sentiment.
Latest Analyst Recommendations
Recent analyst activities reinforce the consistent positive outlook for Regeneron Pharmaceuticals, with the majority maintaining existing recommendations. This aligns with the depicted sentiment trends, reflecting stability and minor shifts in analyst outlooks over time.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-27 | Buy | Buy | Jefferies |
| 2025-08-27 | Outperform | Outperform | Bernstein |
| 2025-08-11 | Buy | Buy | Truist Securities |
| 2025-08-04 | Outperform | Outperform | BMO Capital |
| 2025-08-04 | Buy | Buy | Guggenheim |
Analyst Recommendations with Change of Opinion
Shifts in opinions indicate dynamic market evaluations towards Regeneron. These changes highlight the adaptability of analysts in response to emerging data and market trends, signaling nuanced adjustments in forecasts and sentiment.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-05-30 | Equal Weight | Overweight | Wells Fargo |
| 2025-05-14 | Buy | Neutral | Citigroup |
| 2025-02-05 | Outperform | Market Perform | Leerink Partners |
| 2025-01-16 | Neutral | Buy | UBS |
| 2024-09-24 | Market Perform | Outperform | Leerink Partners |
Interpretation
Overall, the analyst ratings for Regeneron Pharmaceuticals suggest a stable market position with a strong base of support among analysts. The consistent 'Buy' and 'Strong Buy' sentiments reflect enduring investor confidence, despite some fluctuations. A cautious optimism is evident, as reflected in the gradual increase of 'Hold' ratings. This could suggest a balanced mix of caution and optimism, highlighting the need for careful market monitoring as new data emerges.
Conclusion
In conclusion, Regeneron Pharmaceuticals remains a vital player in the biopharmaceutical sector, reflected by mainly positive analyst ratings. While there is a slight shift towards conservative perspectives, the overarching optimism remains driven by the company's strong product portfolio and strategic collaborations. Potential investors might find opportunities in the firm's sustained innovation capacity, whilst keeping in mind the varying risks associated with market dynamics.